Overview

Study of Cemiplimab - TP Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Status:
Not yet recruiting

Trial end date:
2026-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this research study is to determine the safety and tolerability of two dosing schedules of cemiplimab given in combination with cisplatin and docetaxel induction chemotherapy (TPI) in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). Cemiplimab is FDA approved for treatment of basal cell and squamous cell carcinoma of the skin as well as non-small cell lung cancer but not for squamous cell carcinoma of head and neck.

Phase:

Phase 1

Details

Lead Sponsor:

Krzysztof Misiukiewicz

Collaborator:

Regeneron Pharmaceuticals

Treatments:

Cemiplimab
Docetaxel